Evidence map›Paper›PMID 27421768›Full record

ArticleJournal of experimental & clinical cancer research : CR2016

Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.

Bernhard Robl, Sander Martijn Botter, Giovanni Pellegrini, Olga Neklyudova, Bruno Fuchs

Open access · goldAbstract readComparative Study
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Bernhard RoblLaboratory for Orthopedic Research, Department of Orthopedics, Balgrist University Hospital, Forchstrasse 340, Zurich, 8008, Switzerland.
Sander Martijn BotterLaboratory for Orthopedic Research, Department of Orthopedics, Balgrist University Hospital, Forchstrasse 340, Zurich, 8008, Switzerland.
Giovanni PellegriniLaboratory for Animal Model Pathology, Veterinary Pathology, Vetsuisse Faculty, Zurich, Switzerland.
Olga NeklyudovaLaboratory for Orthopedic Research, Department of Orthopedics, Balgrist University Hospital, Forchstrasse 340, Zurich, 8008, Switzerland.
Bruno FuchsLaboratory for Orthopedic Research, Department of Orthopedics, Balgrist University Hospital, Forchstrasse 340, Zurich, 8008, Switzerland. research@balgrist.ch.
Universitätsklinik Balgrist · CHCenter for Pediatric Endocrinology Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteosarcoma is the most common primary malignancy of bone. Its treatment relies on the administration of neoadjuvant and adjuvant chemotherapy combined with surgery. Alternative to common intravenous (i.v.) administration of chemotherapeutic drugs, clinical studies also evaluated the benefit of intraarterial (i.a.) administrations. However, conflicting results were obtained when both routes of administration of cisplatin (CDDP), a gold standard drug in osteosarcoma treatment, were compared. In order to overcome clinical confounding factors, we evaluated both routes of drug administration in a mouse model of experimental osteosarcoma.

methodsWe directly compared i.v. versus i.a. drug infusions of cisplatin (CDDP), in an orthotopic xenograft mouse model of metastatic osteosarcoma. We performed tumor monitoring using caliper and micro computed tomography and measured tumor perfusion using laser speckle contrast imaging. Histopathological changes were evaluated using hematoxylin and eosin staining as well as immunohistochemistry (cleaved PARP-1, CD31, HIF-1α).

resultsFirst, an effective concentration of 4 mg/kg i.a. CDDP was determined that significantly reduced primary tumor volume. We used this concentration of i.a. CDDP and compared it to infusions of i.v. CDDP. Systemic (i.v.) CDDP only showed minor suppression of tumor growth whereas local (i.a.) CDDP strongly inhibited tumor growth and destruction of cortical bone in the tumor-bearing hind limb. Inhibition of tumor growth was linked to a reduced blood perfusion and resulted in increased amounts of tumor necrosis after i.a. CDDP. After treatment with i.a. CDDP, remaining viable tumor tissue responded by increasing expression of HIF-1α. Side effects due to administration of CDDP were minor, showing no differences in kidney damage between i.v. and i.a. CDDP. However, increased epidermal apoptosis in the foot was an indirect marker for locally increased concentrations of CDDP.

conclusionsOur findings demonstrate the great potential of local administration of cytotoxic chemotherapeutics, such as CDDP. Consequently, we provide a preclinical basis for a renewed interest in the clinical use of i.a. chemotherapy in osteosarcoma therapy.

Indexed as

AnimalsAntineoplastic AgentsBone NeoplasmsCell Line, TumorCisplatinGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitInfusions, Intra-ArterialInfusions, IntravenousMiceOsteosarcomaPlatelet Endothelial Cell Adhesion Molecule-1Poly (ADP-Ribose) Polymerase-1Transplantation, HeterologousXenograft Model Antitumor AssaysAntineoplastic AgentsCisplatinHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitPARP1 protein, humanPlatelet Endothelial Cell Adhesion Molecule-1Poly (ADP-Ribose) Polymerase-1CisplatinIntraarterialIntravenousMetastasisOsteosarcoma

Identifiers

PMID27421768
PMCPMC4947253
OpenAlexW2473743997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.